27076-16-0

Usage

Uses

Used in Dye and Pigment Production:
5-ethoxy-2-nitroaniline is used as an intermediate in the production of dyes and pigments for various applications, including textiles, plastics, and printing inks. Its chemical structure allows for the creation of a wide range of colorants with specific properties.
Used in Organic Synthesis:
As a reagent in organic synthesis, 5-ethoxy-2-nitroaniline is utilized for the preparation of various organic compounds. Its presence in reactions can facilitate the formation of desired products through specific chemical pathways.
Used in Analytical Chemistry:
5-ethoxy-2-nitroaniline serves as an analytical reagent for the determination of different substances. Its chemical properties make it suitable for use in analytical techniques to detect or quantify specific compounds in samples.
Safety Considerations:
Due to its potential toxicity and harmful effects, 5-ethoxy-2-nitroaniline must be handled with caution. Proper safety measures should be taken during its use, storage, and transportation to prevent accidents or harm to individuals. Compliance with safety regulations is essential to ensure the safe handling of 5-ethoxy-2-nitroaniline.

Upstream product

• 5391-55-9 3-chloro-4-nitro-phenetole 
• 116496-78-7 N-(5-ethoxy-2-nitrophenyl)acetamide 
• 1635-61-6 5-chloro-2-nitroaniline 
• 141-52-6 sodium ethanolate 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 591-33-3 3-ethoxyacetanilide 
• 7664-93-9 sulfuric acid 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 857629-22-2 5-ethoxy-2-nitro-phenol 
• 579474-22-9 (5-ethoxy-2-nitro-phenyl)-carbamic acid tert-butyl ester 
• 1197-37-1 4-ethoxy-benzene-1,2-diamine 
• 55489-15-1 5-ethoxy-1,3-dihydro-2H-benzo[d]imidazole-2-thione 
• 480441-72-3 7-ethoxy-3-methyl-2-phenylthioquinoxaline 1,4-dioxide 
• 5391-55-9 3-chloro-4-nitro-phenetole 

Relevant academic research and scientific papers

Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport

Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotr

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES

The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a no

Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity

Thirty-six 6(7)-substituted-3-methyl- or 3-halogenomethyl-2-phenylthio-phenylsulphonyl-chloro-quinoxaline 1,4-dioxides belonging to series 3-6 were synthesised and submitted to a preliminary in vitro evaluation for antimycobacterial, anticandida and antibacterial activities. Antitubercular screening showed a generally good activity of 3-methyl-2-phenylthioquinoxaline 1,4-dioxides (3d,e,h-j) against Mycobacterium tuberculosis, and exhibited MIC between 0.39 and 0.78 μg mL-1 (rifampicin MIC=0.25 μg mL-1), whereas in compounds 4d,e, 5a,b,d,e,l and 6b-e,j,l MIC ranged between 1.56 and 6.25 μg mL-1. Results of the antibacterial and anticandida screening showed that 6e and 6l exhibited MIC=0.4 and 1.9 μg mL-1, respectively, against Candida krusei (miconazole MIC=0.9 μg mL-1), and 4i, 5b,d, 6e, MIC=3.9 μg mL-1 against Candida glabrata (miconazole MIC=0.4 μg mL-1), while compounds 3d,l, 5e,l, and 6b,d,e,l showed MIC=15.6 μg mL-1 against Vibrio alginolyticus.